The effects of food and divided dosing on the bioavailability of oral vinorelbine

Eric K. Rowinsky, V. Sol Lucas, Ai Ly Y Hsieh, William A. Wargin, John A. Hohneker, Barbara Lubejko, Susan E. Sartorius, Ross C Donehower

Research output: Contribution to journalArticle

Abstract

The effects of food and divided dosing on the bioavailability of a liquid-filled gelatin capsule formulation of vinorelbine (Navelbine), a semisynthetic vinca alkaloid with broad clinical activity, was evaluated in patients with advanced solid tumors. A group of 13 patients were randomized to treatment with the oral formulation at the recommended phase II dose of 80 mg/m2 per week either in the fasting state or after ingestion of a standard meal. Patients were treated 1 week later in the alternate state relative to their first dose. The effects of divided dosing were assessed during the 3rd week, at which time vinorelbine was administered in two divided doses. After the completion of pharmacokinetic and bioavailability studies, patients received the oral formulation at a dose of 80 mg/m2 per week in two divided doses to evaluate the feasibility of chronic oral drug administration. Both manipulations resulted in small, albeit statistically significant, reductions in the relative bioavailability of this oral formulation. The relative bioavailability decreased by 22 ± 28% when treatment followed the ingestion of a standard meal, possibly due to a delay in gastrointestinal transit time. The mean time of maximum plasma concentration (T(max)) increased from 1.3 ± 1.6 h in the fasting state to 2.5 ± 1.6 h in the fed state, although this difference was not statistically significant. Similarly, the relative bioavailability declined by 16 ± 51% when vinorelbine was administered in two divided doses. An analysis of dose proportionality revealed disproportionate increases in dose-normalized C(max) and AUC values with single oral doses above 120 mg, which may account for this phenomenon. The high clearance of vinorelbine, which approaches hepatic blood flow, and the lack of dose proportionality after oral administration, indicate that there is a large first-pass effect which may be saturable, or nonlinear, above single doses of 120 mg. In addition, the toxicological and pharmacological characteristics of oral vinorelbine indicate that treatment after a standard meal or on a divided dosing schedule is safe. Chronic oral administration of the agent in two divided doses was also well tolerated. However, the small reduction in the relative bioavailability following the ingestion of a standard meal and with divided dosing suggest the need for further pharmacodynamic studies to determine if reductions in drug exposure of this magnitude may portend diminished antitumor activity.

Original languageEnglish (US)
Pages (from-to)9-16
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume39
Issue number1-2
DOIs
StatePublished - 1996

Fingerprint

Biological Availability
Food
Meals
Oral Administration
Eating
Fasting
Pharmacodynamics
Gastrointestinal Transit
Vinca Alkaloids
Pharmacokinetics
Gelatin
Pharmaceutical Preparations
Toxicology
Area Under Curve
Capsules
vinorelbine
Tumors
Appointments and Schedules
Blood
Therapeutics

Keywords

  • Bioavailability
  • Divided dosing
  • Food
  • Navelbine
  • Oral
  • Pharmacokinetics
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Rowinsky, E. K., Lucas, V. S., Hsieh, A. L. Y., Wargin, W. A., Hohneker, J. A., Lubejko, B., ... Donehower, R. C. (1996). The effects of food and divided dosing on the bioavailability of oral vinorelbine. Cancer Chemotherapy and Pharmacology, 39(1-2), 9-16. https://doi.org/10.1007/s002800050532

The effects of food and divided dosing on the bioavailability of oral vinorelbine. / Rowinsky, Eric K.; Lucas, V. Sol; Hsieh, Ai Ly Y; Wargin, William A.; Hohneker, John A.; Lubejko, Barbara; Sartorius, Susan E.; Donehower, Ross C.

In: Cancer Chemotherapy and Pharmacology, Vol. 39, No. 1-2, 1996, p. 9-16.

Research output: Contribution to journalArticle

Rowinsky, EK, Lucas, VS, Hsieh, ALY, Wargin, WA, Hohneker, JA, Lubejko, B, Sartorius, SE & Donehower, RC 1996, 'The effects of food and divided dosing on the bioavailability of oral vinorelbine', Cancer Chemotherapy and Pharmacology, vol. 39, no. 1-2, pp. 9-16. https://doi.org/10.1007/s002800050532
Rowinsky, Eric K. ; Lucas, V. Sol ; Hsieh, Ai Ly Y ; Wargin, William A. ; Hohneker, John A. ; Lubejko, Barbara ; Sartorius, Susan E. ; Donehower, Ross C. / The effects of food and divided dosing on the bioavailability of oral vinorelbine. In: Cancer Chemotherapy and Pharmacology. 1996 ; Vol. 39, No. 1-2. pp. 9-16.
@article{0e3b017033d54f7584546072054c5d94,
title = "The effects of food and divided dosing on the bioavailability of oral vinorelbine",
abstract = "The effects of food and divided dosing on the bioavailability of a liquid-filled gelatin capsule formulation of vinorelbine (Navelbine), a semisynthetic vinca alkaloid with broad clinical activity, was evaluated in patients with advanced solid tumors. A group of 13 patients were randomized to treatment with the oral formulation at the recommended phase II dose of 80 mg/m2 per week either in the fasting state or after ingestion of a standard meal. Patients were treated 1 week later in the alternate state relative to their first dose. The effects of divided dosing were assessed during the 3rd week, at which time vinorelbine was administered in two divided doses. After the completion of pharmacokinetic and bioavailability studies, patients received the oral formulation at a dose of 80 mg/m2 per week in two divided doses to evaluate the feasibility of chronic oral drug administration. Both manipulations resulted in small, albeit statistically significant, reductions in the relative bioavailability of this oral formulation. The relative bioavailability decreased by 22 ± 28{\%} when treatment followed the ingestion of a standard meal, possibly due to a delay in gastrointestinal transit time. The mean time of maximum plasma concentration (T(max)) increased from 1.3 ± 1.6 h in the fasting state to 2.5 ± 1.6 h in the fed state, although this difference was not statistically significant. Similarly, the relative bioavailability declined by 16 ± 51{\%} when vinorelbine was administered in two divided doses. An analysis of dose proportionality revealed disproportionate increases in dose-normalized C(max) and AUC values with single oral doses above 120 mg, which may account for this phenomenon. The high clearance of vinorelbine, which approaches hepatic blood flow, and the lack of dose proportionality after oral administration, indicate that there is a large first-pass effect which may be saturable, or nonlinear, above single doses of 120 mg. In addition, the toxicological and pharmacological characteristics of oral vinorelbine indicate that treatment after a standard meal or on a divided dosing schedule is safe. Chronic oral administration of the agent in two divided doses was also well tolerated. However, the small reduction in the relative bioavailability following the ingestion of a standard meal and with divided dosing suggest the need for further pharmacodynamic studies to determine if reductions in drug exposure of this magnitude may portend diminished antitumor activity.",
keywords = "Bioavailability, Divided dosing, Food, Navelbine, Oral, Pharmacokinetics, Vinorelbine",
author = "Rowinsky, {Eric K.} and Lucas, {V. Sol} and Hsieh, {Ai Ly Y} and Wargin, {William A.} and Hohneker, {John A.} and Barbara Lubejko and Sartorius, {Susan E.} and Donehower, {Ross C}",
year = "1996",
doi = "10.1007/s002800050532",
language = "English (US)",
volume = "39",
pages = "9--16",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1-2",

}

TY - JOUR

T1 - The effects of food and divided dosing on the bioavailability of oral vinorelbine

AU - Rowinsky, Eric K.

AU - Lucas, V. Sol

AU - Hsieh, Ai Ly Y

AU - Wargin, William A.

AU - Hohneker, John A.

AU - Lubejko, Barbara

AU - Sartorius, Susan E.

AU - Donehower, Ross C

PY - 1996

Y1 - 1996

N2 - The effects of food and divided dosing on the bioavailability of a liquid-filled gelatin capsule formulation of vinorelbine (Navelbine), a semisynthetic vinca alkaloid with broad clinical activity, was evaluated in patients with advanced solid tumors. A group of 13 patients were randomized to treatment with the oral formulation at the recommended phase II dose of 80 mg/m2 per week either in the fasting state or after ingestion of a standard meal. Patients were treated 1 week later in the alternate state relative to their first dose. The effects of divided dosing were assessed during the 3rd week, at which time vinorelbine was administered in two divided doses. After the completion of pharmacokinetic and bioavailability studies, patients received the oral formulation at a dose of 80 mg/m2 per week in two divided doses to evaluate the feasibility of chronic oral drug administration. Both manipulations resulted in small, albeit statistically significant, reductions in the relative bioavailability of this oral formulation. The relative bioavailability decreased by 22 ± 28% when treatment followed the ingestion of a standard meal, possibly due to a delay in gastrointestinal transit time. The mean time of maximum plasma concentration (T(max)) increased from 1.3 ± 1.6 h in the fasting state to 2.5 ± 1.6 h in the fed state, although this difference was not statistically significant. Similarly, the relative bioavailability declined by 16 ± 51% when vinorelbine was administered in two divided doses. An analysis of dose proportionality revealed disproportionate increases in dose-normalized C(max) and AUC values with single oral doses above 120 mg, which may account for this phenomenon. The high clearance of vinorelbine, which approaches hepatic blood flow, and the lack of dose proportionality after oral administration, indicate that there is a large first-pass effect which may be saturable, or nonlinear, above single doses of 120 mg. In addition, the toxicological and pharmacological characteristics of oral vinorelbine indicate that treatment after a standard meal or on a divided dosing schedule is safe. Chronic oral administration of the agent in two divided doses was also well tolerated. However, the small reduction in the relative bioavailability following the ingestion of a standard meal and with divided dosing suggest the need for further pharmacodynamic studies to determine if reductions in drug exposure of this magnitude may portend diminished antitumor activity.

AB - The effects of food and divided dosing on the bioavailability of a liquid-filled gelatin capsule formulation of vinorelbine (Navelbine), a semisynthetic vinca alkaloid with broad clinical activity, was evaluated in patients with advanced solid tumors. A group of 13 patients were randomized to treatment with the oral formulation at the recommended phase II dose of 80 mg/m2 per week either in the fasting state or after ingestion of a standard meal. Patients were treated 1 week later in the alternate state relative to their first dose. The effects of divided dosing were assessed during the 3rd week, at which time vinorelbine was administered in two divided doses. After the completion of pharmacokinetic and bioavailability studies, patients received the oral formulation at a dose of 80 mg/m2 per week in two divided doses to evaluate the feasibility of chronic oral drug administration. Both manipulations resulted in small, albeit statistically significant, reductions in the relative bioavailability of this oral formulation. The relative bioavailability decreased by 22 ± 28% when treatment followed the ingestion of a standard meal, possibly due to a delay in gastrointestinal transit time. The mean time of maximum plasma concentration (T(max)) increased from 1.3 ± 1.6 h in the fasting state to 2.5 ± 1.6 h in the fed state, although this difference was not statistically significant. Similarly, the relative bioavailability declined by 16 ± 51% when vinorelbine was administered in two divided doses. An analysis of dose proportionality revealed disproportionate increases in dose-normalized C(max) and AUC values with single oral doses above 120 mg, which may account for this phenomenon. The high clearance of vinorelbine, which approaches hepatic blood flow, and the lack of dose proportionality after oral administration, indicate that there is a large first-pass effect which may be saturable, or nonlinear, above single doses of 120 mg. In addition, the toxicological and pharmacological characteristics of oral vinorelbine indicate that treatment after a standard meal or on a divided dosing schedule is safe. Chronic oral administration of the agent in two divided doses was also well tolerated. However, the small reduction in the relative bioavailability following the ingestion of a standard meal and with divided dosing suggest the need for further pharmacodynamic studies to determine if reductions in drug exposure of this magnitude may portend diminished antitumor activity.

KW - Bioavailability

KW - Divided dosing

KW - Food

KW - Navelbine

KW - Oral

KW - Pharmacokinetics

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0029820708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029820708&partnerID=8YFLogxK

U2 - 10.1007/s002800050532

DO - 10.1007/s002800050532

M3 - Article

C2 - 8995494

AN - SCOPUS:0029820708

VL - 39

SP - 9

EP - 16

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1-2

ER -